• Publications
  • Influence
Expression of vasoactive intestinal peptide (VIP) receptors in human uterus
We show the existence of functional vasoactive intestinal peptide (VIP) receptors in normal human female genital tract (endometrium, myometrium, ovary and Fallopian tube) as well as in leiomyoma (aExpand
  • 26
  • 4
Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers
The overexpression of angiogenic factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and insulin-like growth factors (IGFs) plays a role in the migration andExpand
  • 48
  • 3
Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells
We analyzed the cross-talk between receptors for vasoactive intestinal peptide (VIP) and the human epidermal growth factor family of tyrosine kinase receptors (HER) in oestrogen-dependent (T47D) andExpand
  • 39
  • 3
Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer
Vasoactive intestinal peptide (VIP) and its receptors (VPACs) are involved in proliferation, survival, and differentiation in human breast cancer cells. Its mechanism of action is traditionallyExpand
  • 49
  • 2
Vasoactive intestinal peptide behaves as a pro‐metastatic factor in human prostate cancer cells
There is little known on the involvement of vasoactive intestinal peptide (VIP) in the metastatic cascade of human prostate cancer, that is, cell proliferation, cell–cell adhesion,Expand
  • 25
  • 2
Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells
Previous studies have shown that vasoactive intestinal peptide (VIP) and its receptors (VPAC(1) and VPAC(2) receptors) are involved in promotion and growth of many human tumours including breastExpand
  • 28
  • 2
Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN‐215) and a bombesin antagonist (RC‐3095)
Bombesin (BN) and gastrin‐releasing peptide (GRP) have been shown to stimulate the growth of human prostate cancer in vivo and in vitro by mechanisms initiated by binding of the peptide to BN/GRPExpand
  • 18
  • 2
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers
The antiproliferative effects of an antagonist of growth hormone-releasing hormone (GHRH) JV-1-38 were evaluated in nude mice bearing s.c. xenografts of LNCaP and MDA-PCa-2b human androgen-sensitiveExpand
  • 70
  • 1
  • PDF
Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
PURPOSE The receptors for luteinizing hormone-releasing hormone receptor (LHRH-R) are found in >50% of human breast cancers. Doxorubicin (DOX) was linked to [D-Lys(6)]LHRH to form a cytotoxicExpand
  • 45
  • 1
  • PDF
Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
Clear renal cell carcinoma (cRCC) is an aggressive and fatal neoplasm. The present work was undertaken to investigate the antiproliferative potential of vasoactive intestinal peptide (VIP) exposureExpand
  • 19
  • 1